Part 1 Plenary lectures: pathogenesis of complications in NIDDM, N. Sakamoto; drug therapy in NIDDM - update, T. Kaneko. Part 2 Luncheon lectures: model care of NIDDM in 1993, J.R. Turtle et al; animal models of NIDDM - what did GK rats teach us?, T. Toyota. Part 3 Frontiers of diabetes research: current concepts of the role of polyol metabolism and related metabolic abnormalities in diabetic complications, J.R. Williamson et al; the glucose transporter family, D.E. James. Part 4 New insights of diabetes treatment and care: treatment of hyperlipidemia and atherosclerosis in NIDDM, Y. Akanuma; the relevance of the St. Vincent declaration to world wide NIDDM care, J. Jervell. Part 5 Etiology and pathogenesis of NIDDM: clinical and genetic analysis of mitochondrial DNA mutation in patients with diabetes mellitus, Y. Nakagawa et al; new efficient assay for aldose reductase activity, Y. Hamada et al; sleep disordered breathing and impaired glucose tolerance of aged patients with cerebrovascular diseases, K. Katsumata et al; fat distribution in NIDDM - comparison between insulin and sulfonylurea treatment, A. Yamauchi et al. Part 6 Insulin action and its related-regulatory mechanisms: different processing of abnormal insulin receptors with mutations at the extracellular domain and the intracellular domain, M. Kobayashi et al; insulin therapy in NIDDM - attempt to restore insulin secretion and to augment hepatic glucose uptake, R. Kawamori et al; insulin resistance rather than hyperinsulinemia contributory to essential hypertension, C. Yokota et al; completely noninvasive measurements of human blood glucose in vivo using near infrared waves, M. Noda et al. Part 7 New aspects of treatment in NIDDM: national implementation of a structured treatment and teaching programme (TTP) for NIDDM in Germany, I. Mulhauser et al; beneficial effects of biguanides on diabetic patients with and without insulin treatment, S. Kawazu et al; comparison between effects of glimepiride and glibenclamide on in vivo insulin action, J. Sato et al; clinical applications of the wearable artificial endocrine pancreas with the newly designed needle-type glucose sensor, K. Nishida et al. Part 8 Risk factors of atherosclerosis in NIDDM: study on standard treatment lipid levels in diabetics, C. Ito et al; plasminogen activator inhibitor-1 and fasting plasma insulin levels in NIDDM, F. Nakaya et al. Part 9 NIDDM and diabetic complications: effects of epalrestat on early diabetic nephropathy in clinical and experimental studies, S. Isogai et al; observation of the intimal thickening of diabetic rats after denudation of the endothelium, S. Nakamoto et al; changes in diabetic retinopathy in patients undergoing rapid glycemic control during pregnancy, M. Shimizu et al; pancreatic cancer screened by ultrasonography in diabetics, Y. Atsumi et al. (Part Contents).
